Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

June 25, 2015

Ocata Therapeutics CEO rings NASDAQ opening bell

Courtesy photo Paul K. Wotton, center, and employees of Ocata Therapeutics of Marlborough, participate in the opening bell ceremony at the NASDAQ Marketsite in New York City.

Paul K. Wotton, president and CEO of Ocata Therapeutics, rang the opening bell at the NASDAQ Marketside in New York City Wednesday morning.

"We are pleased to have been invited to open the NASDAQ and as a leader in regenerative ophthalmology are delighted to be part of this leading stock exchange," Paul K. Wotton, president and CEO of Ocata Therapeutics, said in a statement released before the ceremony.

The NASDAQ hosts opening and closing bell ceremonies to give listed companies wide exposure, celebrate milestones and make news announcements, according to the NASDAQ.

The ceremony comes shortly after Marlborough-based Ocata, a leader in stem-cell treatment for degenerative diseases causing blindness, announced it expects to net more than $30 million in a common stock offering to fund its clinical activities. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, according to the company, which was formerly known as Advanced Cell Technology.

“We expect to strengthen our balance sheet as a result of our recently announced equity financing and are thus well poised to commence the next phase of our clinical trials … so that we may one day bring an effective treatment to so many patients in need,” Wotton said.

Sign up for Enews


Order a PDF